| Literature DB >> 29997509 |
Jianbo Fu1, Jing Tang1,2, Yunxia Wang1, Xuejiao Cui1,2, Qingxia Yang1,2, Jiajun Hong1, Xiaoxu Li1,2, Shuang Li1,2, Yuzong Chen3, Weiwei Xue2, Feng Zhu1,2.
Abstract
Sequential windowed acquisition of all theoretical fragment ion mass spectra (SWATH-MS) has emerged as one of the most popular techniques for label-free proteome quantification in current pharmacoproteomic research. It provides more comprehensive detection and more accurate quantitation of proteins comparing with the traditional techniques. The performance of SWATH-MS is highly susceptible to the selection of processing method. Till now, ≥27 methods (transformation, normalization, and missing-value imputation) are sequentially applied to construct numerous analysis chains for SWATH-MS, but it is still not clear which analysis chain gives the optimal quantification performance. Herein, the performances of 560 analysis chains for quantifying pharmacoproteomic data were comprehensively assessed. Firstly, the most complete set of the publicly available SWATH-MS based pharmacoproteomic data were collected by comprehensive literature review. Secondly, substantial variations among the performances of various analysis chains were observed, and the consistently well-performed analysis chains (CWPACs) across various datasets were for the first time generalized. Finally, the log and power transformations sequentially followed by the total ion current normalization were discovered as one of the best performed analysis chains for the quantification of SWATH-MS based pharmacoproteomic data. In sum, the CWPACs identified here provided important guidance to the quantification of proteomic data and could therefore facilitate the cutting-edge research in any pharmacoproteomic studies requiring SWATH-MS technique.Entities:
Keywords: SWATH-MS; normalization; pharmacoproteomics; processing method; transformation
Year: 2018 PMID: 29997509 PMCID: PMC6028727 DOI: 10.3389/fphar.2018.00681
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Seven SWATH-MS based benchmark pharmacoproteomic datasets collected for the analysis of this study.
| Datasets | PRIDE ID | Sample size and Dataset description | Analysis Chain | Instrument |
|---|---|---|---|---|
| PXD002952 | 3 samples of 65% human, 30% yeast, and 5% | LOG-MED-??? | TripleTOF 6600 | |
| 34:1130-6, 2016 | 3 samples of 65% human, 15% yeast, and 20% | |||
| PXD003278 | 6 siRNA-treated Cal51 cell samples | LOG-QUA-NON | TripleTOF 5600 | |
| 20:1229-41, 2017 | 6 PRPF8-depleted Cal51 cell samples | |||
| PXD006106 | 10 formaldehyde treated HeLa Kyoto cell samples | LOG-MED-NON | TripleTOF 5600 | |
| 169:1105-18, 2017 | 10 formaldehyde untreated HeLa Kyoto cell samples | |||
| PXD000672 | 18 tumorous kidney tissue biopsies | LOG-QUA-NON | TripleTOF 5600 | |
| 21:407-13, 2015 | 18 non-tumorous kidney tissue biopsies | |||
| PXD004880 | 18 plasma samples from individuals with | LOG-MED-NON | TripleTOF 5600 | |
| 7:14818, 2017 | 18 plasma samples from healthy controls | |||
| PXD003972 | 20 wild type mouse samples | LOG-???-??? | TripleTOF 5600 | |
| 18:3219-26, 2017 | 20 knock-in mouse samples expressing endogenous GRB2 | |||
| PXD001064 | 72 blood samples of monozygotic twins | ???-RLR-BAK | TripleTOF 5600 | |
| 11:786, 2015 | 44 blood samples of dizygotic twins |